Gates Foundation Strategic Investment Fund Logo
Share this page:


									kymab logo

Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies. For the foundation, this platform could lead to the discovery of drugs and vaccines for the foundation’s priority infectious diseases such as HIV, malaria, TB, pertussis, and neonatal sepsis.

Investment Date: January 2014

Press Release
Case Study